I-O newcomer's funding now nearly $170 million

22 March 2018
2019_biotech_test_vial_discovery_big

TCR2 Therapeutics Inc, an immuno-oncology (I-O) company claiming to be developing a new class of T cell receptor (TCR)-based cellular therapies for both solid tumors and blood cancers, has completed an oversubscribed Series B financing of $125 million.

The funds will advance the US biotech’s TRuC-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology